| 14.87 1.13 (8.22%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.32 | 1-year : | 21.39 |
| Resists | First : | 15.68 | Second : | 18.32 |
| Pivot price | 13.95 |
|||
| Supports | First : | 12.89 | Second : | 11.17 |
| MAs | MA(5) : | 14.17 |
MA(20) : | 14.13 |
| MA(100) : | 10.12 |
MA(250) : | 13.38  |
|
| MACD | MACD : | 0.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 59.2 |
D(3) : | 54.4 |
| RSI | RSI(14): 60.2 |
|||
| 52-week | High : | 27.23 | Low : | 6.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XNCR ] has closed below upper band by 14.1%. Bollinger Bands are 3.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.03 - 15.12 | 15.12 - 15.2 |
| Low: | 13.64 - 13.74 | 13.74 - 13.83 |
| Close: | 14.71 - 14.86 | 14.86 - 15.01 |
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Mon, 10 Nov 2025
Xencor to Participate at Upcoming Investor Conferences - Business Wire
Mon, 10 Nov 2025
Wedbush Estimates Xencor's FY2025 Earnings (NASDAQ:XNCR) - MarketBeat
Fri, 07 Nov 2025
Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
Thu, 06 Nov 2025
Xencor (XNCR) Analyst Rating Update: RBC Capital Raises Price Ta - GuruFocus
Thu, 06 Nov 2025
Decoding Xencor Inc (XNCR): A Strategic SWOT Insight - GuruFocus
Wed, 05 Nov 2025
Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 117.4 (%) |
| Shares Short | 8,050 (K) |
| Shares Short P.Month | 9,590 (K) |
| EPS | -2.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.69 |
| Profit Margin | -116.5 % |
| Operating Margin | -76.1 % |
| Return on Assets (ttm) | -10.5 % |
| Return on Equity (ttm) | -29.3 % |
| Qtrly Rev. Growth | 82.4 % |
| Gross Profit (p.s.) | -1.16 |
| Sales Per Share | 2.06 |
| EBITDA (p.s.) | -1.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -131 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -6.31 |
| PEG Ratio | 0 |
| Price to Book value | 1.7 |
| Price to Sales | 7.21 |
| Price to Cash Flow | -8.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|